| 1 | Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy(STRATEGY):a multicenter,randomized,controlled,non-inferiority clinical trial显示文摘Despite the current guideline's recommendation of a timely stepwise intensification therapy,the 'clinical inertia',termed as the delayed treatment intensification,commonly exists in the real world,which may be partly due to the relatively little substantial evidence and no clear consensus regarding the efficacy and safety of triple oral agents in patients inadequately controlled with dual therapy.In this clinical trial performed in 237 centers in China,5,535 type 2 diabetic patients inadequately controlled by previous therapies were treated with a stable metformin/sitagliptin dual therapy for 20 weeks.The patients who did not reach the glycated hemoglobin A1c(HbA1c) goal were then further randomized into glimepiride,gliclazide,repaglinide,or acarbose group for an additional 24-week triple therapy.A mean HbAlc reduction of 0.85%was observed when sitagliptin was added to the patients inadequately controlled with metformin in 16 weeks.Further HbAlc reductions in the 24-week triple therapy stage were 0.65%in glimepiride group,0.70%in gliclazide group,0.61%in repaglinide group,and 0.45%in acarbose group.The non-inferiority criterion for primary hypotheses was met for gliclazide and repaglinide,but not for acarbose,compared with glimepiride,when added to metformin/sitagliptin dual therapy.The incidences of adverse events(AEs) were 29.2%in the dual therapy stage and30.3%in the triple therapy stage.Metformin/sitagliptin as baseline therapy,with the addition of a third oral antihyperglycemic agent,including glimepiride,gliclazide,repaglinide,or acarbose,was effective,safe and well-tolerated for achieving an HbAlc<7.0%goal in type 2 diabetic patients inadequately controlled with previous therapies.The timely augmentation of up to three oral antihyperglycemic agents is valid and of important clinical benefit to prevent patients from exposure to unnecessarily prolonged hyperglycemia. | Wen Xu Yiming Mu Jiajun Zhao Dalong Zhu Qiuhe Ji Zhiguang Zhou Bin Yao Anhua Mao Samuel S.Engel Bin Zhao Yan Bi Longyi Zeng Xingwu Ran Juming Lu Linong Ji Wenying Yang Weiping Jia Jianping Weng | 2017 | Science China(Life Sciences)2017，60，3： | 19 |
| 2 | Electrospun Polyethylene Glycol/Polyvinyl Alcohol Composite Nanofibrous Membranes as Shape-Stabilized Solid-Solid Phase Change Materials显示文摘In this work,shape-stabilized solid-solid phase change materials(PCMs)were fabricated by simply electrospinning polyethylene glycol(PEG)and polyvinyl alcohol(PVA).Owing to the strong hydrogen bonds and entanglement between those molecular chains of PEG and PVA,PEG was packaged by PVA.The morphological structures,thermal stability and thermal energy storage properties of those fibers were investigated.SEM results showed that those electrospun PVA/PEG composite membranes hold a three-dimensional nonwoven web structure even the content of PEG as high as 70%.The thermal energy storage ability of those composite fibers increased with the increase of the content of PEG.The heat enthalpies of PEG/PVA=7/3 were as high as 78.806 J/g.Moreover,those composite fibers had excellent thermal stability.After 100 heating and cooling cycles,there was almost no obvious change in the melting enthalpy and crystallization enthalpy.Those fibers still maintained good thermal regulation.The simple preparation process,low cost of raw materials and excellent stability endow the PCMs great utilization potentiality in smart textile and energy storage systems. | Junwen Huang Houyong Yu Somia Yassin Hussain Abdalkarim Jaromir Marek Jiri Militky Yingzhan Li Juming Yao | 2020 | Advanced Fiber Materials2020，2，3： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员